Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Since AHA 2011 five interesting studies have been presented or published on the efficacy and safety of novel antithrombotic strategies.
When compared to aspirin routine oral anticoagulation for heart failure in sinus rhythm reduces ischemic stroke but at the cost of increased but not intracranial bleeding, and thus cannot be advised. The trade-off of aspirin versus no antithrombotic therapy at all remains to be established.
For patients with symptomatic pulmonary embolism a new oral treatment regimen has been developed. In the EINSTEIN-PE trial 4,831 patients with acute symptomatic pulmonary embolism were randomized to oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mgonce daily), or to subcutaneous enoxaparin followed by a vitamin K antagonist for 3, 6, or 12 months.3For the primary efficacy outcome (symptomatic recurrent venous thromboembolism) rivaroxaban was non-inferior to control: 50 events with rivaroxaban (2.1%) and 44 events in the standard-therapy group (1.8%) : HR 1.12, 95% CI 0.75- 1.68, noninferiority margin, 2.0, p = 0.003, figure 2). Major bleeding wasseen in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the control group (HR 0.49, 95% CI 0.31- 0.79, p = 0.003, figure 3). Intracranial hemorrhage occurred in 1 patient in the rivaroxaban group and in 10 in the control arm (p = 0.005)
Thus, rivaroxaban is a simple oral and effective alternative to enoxaparin/warfarin in the prevention of recurrent thromboembolism in symptomatic patients with pulmonary embolism with an excellent safety profile including intracranial hemorrhage.
From the well-known TRITON trial on prasugrel versus clopidogrel in ACS patients undergoing PCI the CABG data have became available and were published.4 The TRITON-CABG cohort consisted of 346 patients (2.5% of the TRITON population) that underwent isolated CABG during the trial. At least one dose of clopidogrel/prasugrel in the last 7 days prior to surgery was given in over 70% of patients. There were no differences in time to last drug before CABG. Chest tube drainage per patient was increased by prasugrel (655 + 580 ml vs. 503 + 378 ml, p = 0.05), whereas red cell transfusion was similar (2.1% vs. 1.7%, p = 0.44). Re-exploration for bleeding had to be done in 11 prasugrel patients and in 4 on clopidogrel. However, there was a striking difference in all-cause mortality (figure 4)
Despite more bleeding and re-exploration prasugrel showed lower early and long-term mortality after CABG for prior ACS. The same observation on early and late mortality benefit with ticagrelor was done in the much larger CABG cohort in PLATO (n = 1,261) without an increase in major bleeding5. This raises the question whether the stronger platelet inhibitors are more protective in coronary surgery after ACS, or that clopidogrel has an inherent harm in CABG.
In patients with ACS the new platelet P2Y12 receptor blockers ticagrelor and prasugrel are superior over clopidogrel in the prevention of death5 and MI6,7 Prasugrel had only been tested in patients undergoing PCI for ACS and its role in ACS managed medically was unclear so far. In the TRILOGY study 7,243 patients younger than of 75 years on aspirin for with NSTE-ACS managed medically prasugrel 10 mg qd was given for a maximum of 30 months and compared to clopidogrel 75 mg daily8. Nearly half the patients underwent angiography before randomization that took place 4 days after the index event. Cross-over to an invasive strategy was seen in 8% of patients. At a median follow-up of 15 months the primary endpoint (CV death, MI or stroke) occurred in 13.9% on prasugrel 16.0% with clopidogrel (HR 0.91, 95% CI 0.79-1.05, p = 0.21, figure 5). TIMI major bleeding was similar (1.1% vs 0.8%, HR 1.31, 95% CI 0.85-2.11, p = 0.27, but TIMI major and minor bleeding was increased by prasugrel (1.9% vs 1.3%, HR 1.54, 95% CI 1.06-2.23, p = 0.02). Rates of life-threatening, fatal or intracranial bleeding were similar.
Fig 5. CV death, MI, stroke and TIMI major bleeding in TRILOGY
Thus, routine prasugrel in NSTE-ACS patients managed medically is not superior to clopidogrel with regard to CV death, MI or stroke, but at the cost of more major and minor bleeding. These results are at odds with those in ACS patients managed medically with ticagrelor9. But in that large PLATO substudy (n= 5,216) ticagrelor was given very early after presentation, the crossover rate to angiography was 40% and the risk was higher (CV death at 1 year with clopidogrel 7.2% versus 4% in TRILOGY). The lack of benefit of a stronger platelet inhibition in this condition was also seen in GUSTO-IV ACS, where abciximab was given in a mainly non-intervened poluation10. Apparently, clopidogrel is still the best antiplatelet treatment in ACS treated medically.
Oral anticoagulation is required in patients with mechanical heart valves and in most patients with atrial fibrillation. When such patients have to undergo PCI with stenting, also aspirin and clopidogrel are indicated. However, this triple therapy is known to increase the risk of serious bleeding. Omitting oral anticoagulants may lead to an increased risk for ischemic stroke and death, whereas clopidogrel is essential in the prevention of stent thrombosis. Therefore omitting aspirin in warfarin patients with coronary artery disease may be an option given the favorable results of two large randomized post-infarct trials11,12, in which full intensity oral anticoagulation alone was superior to aspirin in reducing reinfarction and stroke. Withholding aspirin in stented patients was tested against triple therapy (warfarin, clopidogrel and aspirin) in the WOEST trial presented at ESC 2012.In this open-label multicenter study 573 patients on oral anticoagulants undergoing stenting were randomized to clopidogrel alone (dual therapy), or to clopidogrel plus low-dose aspirin (triple therapy). At 1 year the primary outcome (TIMI major, minor and minimal bleeding) occurred in 19.5% in the dual therapy group and in 44.9 % in the triple therapy group (HR = 0.36, 95%CI 0.26-0.50, NNT = 4, figure 6). MI (3.3% vs 4.7%), stroke (1.1% vs 2.9%), target vessel revascularization (6.2% vs 5.7%), or stent thrombosis (1.5% vs 3.2%) did not differ significantly between the groups, but all-cause mortality at 1 year was lower in the dual therapy group than in the triple therapy group (2.5% vs 6.4%, NNT = 26, p = 0.027).
Thus, triple therapy after stenting in warfarin-treated patients doubles the bleeding rate when compared to dual therapy where aspirin is left out (NNH = 4). Although the excess bleeding was not unexpected, this the first study to confirm the risk in a randomized quantitative way. Interestingly, thrombotic risk including stent thrombosis was not increased by omitting aspirin, and all-cause mortality was more than halved. As shown previously in the pre-clopidogrel era, these results cast doubt about the efficacy and safety of aspirin in coronary patients otherwise protected with oral anticoagulation as well with an alternative platelet inhibitor.
Loh E St John Sutton M, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336: 251-257
Homma S, Thompson JLP, Pullicino PM et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859-1869
EINSTEIN-PE investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-1297
Smith PK. Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass graft cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012;60:388-396
Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-684
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012 in press
James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2012;342:d3527
GUSTO-IV ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-1924
Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002:360:109-113
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974
© 2017 European Society of Cardiology. All rights reserved